Loading...
•
Jan 31, 2023
Cooper Q1 2023 Earnings Report
CooperCompanies reported first quarter results with revenue up 9% and strong operational performances at both CooperVision and CooperSurgical.
Key Takeaways
CooperCompanies announced a 9% increase in revenue to $858.5 million. GAAP diluted EPS was $1.70, while non-GAAP diluted EPS was $2.90. The company's CooperVision and CooperSurgical segments showed revenue increases of 4% and 23%, respectively.
Revenue increased 9% year-over-year to $858.5 million.
CooperVision revenue was up 4% to $581.3 million.
CooperSurgical revenue was up 23% to $277.2 million.
GAAP diluted earnings per share (EPS) was $1.70, down 11% from last year.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Office & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
The Company updated its fiscal year 2023 financial guidance. Fiscal 2023 total revenue of $3,496 - $3,553 million (organic growth of 7% to 9%). Fiscal 2023 non-GAAP diluted earnings per share of $12.60 - $12.90
Positive Outlook
- Fiscal 2023 total revenue of $3,496 - $3,553 million
- Organic growth of 7% to 9%
- CVI revenue of $2,352 - $2,388 million
- Organic growth of 8% to 9% for CVI
- CSI revenue of $1,144 - $1,166 million
Challenges Ahead
- Organic growth of 5% to 7% for CSI
- Fiscal 2023 guidance does not include the Cook Medical Reproductive Health acquisition
- Transaction is pending regulatory approval
- Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets
- Excludes acquisition, integration and manufacturing related costs
Revenue & Expenses
Visualization of income flow from segment revenue to net income